This refresh
Data-driven refresh July 12, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,235 tickers); 1,781 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.2
Health Information Services · price $21.77 · 1Y $24.53 · 5Y $35.91 · 10Y $53.27
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.2x B+ · PEG 0.59 A-
Why now. DOCS is poised to dominate the U.S. physician workflow market thanks to its AI‑driven Ask assistant that embeds evidence‑based data directly into clinicians' daily routines, locking in a captive user base. The platform’s 13.1% YoY revenue growth, razor‑thin 0.59 PEG ratio and a healthy 30.4% profit margin prove the business is scaling profitably, and that compounding engine will keep accelerating as more doctors adopt the integrated tools. The entire thesis hinges on the continued network effect of physicians staying on the only platform that lets them browse, discuss and act on clinical content without leaving their EMR.
Moat. DOCS’ moat stems from its deep integration into physicians’ daily workflow via the HIPAA‑compliant Ask AI and the Scribe documentation tool, creating high switching costs for a user who has built a personalized newsfeed and peer network. This lock‑in fuels a 20.6% ROE, driven by pricing power as the only platform that delivers both clinical content and workflow efficiency to U.S. doctors, a segment competitors struggle to replicate quickly.
Risk. The bear case focuses on the lofty valuation and growth slowdown risk: a forward P/E of 22.2 is premium for a company that just posted a 13.1% revenue gain, and a beta of 1.29 amplifies market volatility. If physician adoption stalls and revenue growth falls below 10% YoY, the stock could retreat toward its 52‑week low of $17.15, confirming the over‑optimistic pricing.
Horizon. 1-3 yr $24.53 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.91 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $53.27 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.6
Software - Application · price $223.64 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 12.8x A · PEG 0.61 A-
Why now. Adobe's core strength in empowering content creation and customer experience through its Digital Media and Digital Experience segments continues to generate substantial free cash flow, currently at $10.3b. This cash flow supports a compelling valuation, evidenced by a low PEG ratio of 0.61 and a P/E of 12.8, which is remarkably cheap for a company sustaining 11.5% revenue growth. The thesis rests on the persistent demand for its integrated creative and marketing platforms, ensuring continued compounding of its subscription revenue base.
Moat. Adobe's moat stems from the deep integration and essential nature of its Digital Media and Digital Experience platforms within professional workflows. The comprehensive suite of products for content creation, publishing, and customer experience management creates high switching costs for photographers, video editors, and brands, making its offerings indispensable. This entrenched position and pricing power are reflected in an exceptional ROE of 62.8%, demonstrating its ability to generate significant returns on shareholder capital.
Risk. The bear case for Adobe centers on the potential for increased competition and technological disruption within its core Digital Media and Digital Experience segments, which could erode its pricing power and growth trajectory. While revenue growth remains at 11.5%, the company's beta of 1.43 suggests it is highly sensitive to market shifts and competitive threats, particularly from emerging solutions that could unbundle its integrated platforms. A sustained deceleration in subscription revenue growth, especially if accompanied by margin compression, would confirm the bear thesis and signal a weakening of its market position.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89.2
Software - Application · price $274.96 · 1Y $484.73 · 5Y $709.70 · 10Y $1,053
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 16.8x A- · PEG 0.71 A-
Why now. Intuit’s growth engine is the QuickBooks ecosystem, where SMBs lock in a suite of accounting, payroll and payment tools that expand revenue each year; the business is delivering 15.1% YoY revenue growth, 22.2% ROE and trades at a modest PE of 16.8x, all of which signal a high‑margin, cash‑generating compounder. The compounding persists because each new QuickBooks Online subscriber adds recurring subscription dollars and cross‑sell opportunities into Mailchimp and financing services, creating a virtuous loop of stickier spend. The thesis hinges on the ability to keep the SMB base expanding while deepening wallet share.
Moat. QuickBooks and Mailchimp form an integrated platform that embeds Intuit into the daily financial workflow of small‑ and mid‑market firms, creating switching costs that are hard for rivals to match. The subscription‑based model yields predictable cash flow, and the high ROE of 22.2% stems from pricing power in a category where Intuit is the de‑facto standard for bookkeeping, payroll and merchant processing, limiting competitive encroachment.
Risk. A bear would point to the SMB market’s sensitivity to economic downturns; a slowdown could shave revenue growth below the current 15.1% YoY pace and compress margins, while the stock’s beta of 1 means it will track any broader market weakness. The wide analyst target range ($275–$921) underscores valuation uncertainty. A confirmed dip in quarterly revenue growth to under 10% would trigger the bear case and invalidate the compounding narrative.
Horizon. 1-3 yr $484.73 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $709.70 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,053 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 89
Software - Infrastructure · price $15.19 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 23.7x B+ · PEG 0.51 A-
Why now. DLocal is a compelling growth story, leveraging its robust payment processing services, including pay-in and pay-out solutions for global merchants, to capture expanding digital commerce. The company's impressive 46.6% FY YoY revenue growth, combined with a healthy 18% profit margin and a remarkably low 0.51 PEG ratio, indicates significant undervaluation for its quality and trajectory. This compounding growth is sustained by the increasing demand for seamless cross-border and local-to-local transactions across diverse end markets like streaming, ride-hailing, and e-learning.
Moat. DLocal's durable edge lies in its comprehensive suite of payment processing services, offering hundreds of alternative payment methods (APMs) for both pay-in and pay-out solutions across diverse global markets. This deep integration, which allows merchants to seamlessly manage cross-border and local-to-local transactions, creates significant switching costs once a platform like dLocal for Platforms is adopted. The exceptional 34.6% Return on Equity reflects the pricing power derived from its specialized infrastructure and the operational leverage gained from its critical role in facilitating global digital commerce.
Risk. The primary bear case for DLocal centers on the intense competition within the global payment processing sector, where larger, more established players could increasingly replicate DLocal's localized APM offerings. While current revenue growth is strong, a deceleration from the 46.6% FY YoY rate would expose the current 23.7 P/E TTM as potentially overvalued for a slowing growth profile. A sustained trend of contracting profit margins, driven by competitive pricing pressures or increased regulatory compliance costs in its diverse operating markets, would be the definitive signal confirming the bear thesis.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
5. NBIX — Neurocrine Biosciences, Inc. · score 87
Drug Manufacturers - Specialty & Generic · price $177.11 · 1Y $197.95 · 5Y $289.82 · 10Y $429.93
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 27.2x B · PEG 0.50 A
Why now. NBIX’s growth engine is its FDA‑approved neuro‑psychiatric franchise—INGREZZA for tardive dyskinesia and Orilissa for endometriosis—fueling a 28.6% YoY revenue expansion, a 21.6% profit margin, and a razor‑thin PEG of 0.5. Those metrics prove the business is compounding earnings faster than peers, and the next wave of label expansions will keep the compounding runway alive.
Moat. The moat sits in deep IP protection and specialist positioning of INGREZZA and Orilissa, which command premium pricing in niche neurological and endocrine markets that are hard for generic entrants to replicate. This pricing power drives a near‑20% ROE (19.6%) and a low‑beta, low‑debt balance sheet (D/E 0.14) that shields cash flow and sustains reinvestment.
Risk. The bull case hinges on continued double‑digit growth, but the market already prices NBIX at a lofty PE of 27.2 and a 52‑week range that still leaves upside limited; any slowdown in revenue growth or a competitive breakthrough in movement‑disorder therapies would compress margins and trigger a sell‑off. A miss of the consensus 1‑yr target of $197.95 would be the first concrete signal that the premium valuation is unjustified.
Horizon. 1-3 yr $197.95 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $289.82 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $429.93 if current growth sustains into durable earnings power.
6. LRN — Stride, Inc. · score 86.7
Education & Training Services · price $91.00 · 1Y $104.65 · 5Y $153.22 · 10Y $227.29
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 14.2x A- · PEG 0.51 A-
Why now. Free cash flow of $414m against a $3.9b market cap implies a compelling FCF yield, especially for a company driving 10.9% revenue growth and a 12.2% profit margin. Stride's comprehensive "integrated package of systems, services, products, and professional expertise" for virtual and blended public schools positions it as a high-quality compounder with a remarkably low 0.51 PEG ratio, indicating significant undervaluation relative to its growth prospects. The crux rests on the persistent demand for its technology-based individualized learning solutions.
Moat. Stride's durable edge stems from its "proprietary and third-party online curriculum, software systems, and educational services" which form an "integrated package of systems, services, products, and professional expertise" for public schools. This comprehensive offering creates high switching costs for clients who rely on Stride to attract, enroll, educate, track progress, and support students, making it difficult for competitors to quickly replicate its full-service model. The company's 18.8% ROE reflects its efficient use of capital in this sticky ecosystem.
Risk. Despite strong current profitability, the significant drop from its 52-week high of $171.17 to the current $91 suggests market concerns about the sustainability of its growth trajectory in a competitive online education landscape. Bears would argue that the current 10.9% revenue growth, while solid, may decelerate faster than anticipated if competition intensifies in the "individual online courses" or "general education market" segments. A sustained decline in new enrollments or a contraction in profit margin below 12.2% due to pricing pressure would confirm the bear case.
Horizon. 1-3 yr $104.65 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $153.22 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $227.29 if current growth sustains into durable earnings power.
7. EXLS — ExlService Holdings, Inc. · score 85.7
Information Technology Services · price $27.30 · 1Y $41.00 · 5Y $60.03 · 10Y $89.05
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 17.4x A- · PEG 0.87 B+
Why now. EXLS is poised to dominate AI‑powered digital operations in the insurance and healthcare verticals, where its claims‑management and actuarial analytics platform locks in multi‑year contracts. The business is growing revenue at 13.4% YoY, converting that into a high ROE of 32.3% while trading at a modest P/E of 17.4 and a sub‑1 PEG of 0.87, proving the growth is cheap. The thesis rests on the compounding effect of expanding AI‑driven services across its four segments, which should keep the revenue runway and margin trajectory firmly upward.
Moat. EXLS’s AI‑driven analytics engine is embedded in core insurance workflows—claims processing, underwriting support, and policy servicing—creating high switching costs for carriers that have integrated the platform into their operational backbone. This data moat fuels pricing power, evident in a 32.3% ROE, and cannot be replicated quickly because it requires years of domain data, regulatory compliance expertise, and entrenched client relationships across North America and Europe.
Risk. The bear case hinges on a slowdown in insurance spend, the company’s primary revenue engine, which would blunt the 13.4% growth rate and pressure the 11.7% profit margin. A modest debt‑to‑equity of 0.67 could become a drag if capital markets tighten, and the current P/E of 17.4, while low for a growth name, may already price in the AI tailwind—any earnings miss would force a re‑rating. A sustained decline in new‑business acquisition contracts would be the trigger that validates this risk.
Horizon. 1-3 yr $41.00 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $60.03 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $89.05 if current growth sustains into durable earnings power.
8. NVDA — NVIDIA Corporation · score 85.1
Semiconductors · price $210.96 · 1Y $301.62 · 5Y $441.60 · 10Y $655.09
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 32.3x B · PEG 0.65 A-
Why now. NVIDIA's dominance in data center scale AI infrastructure is driving unparalleled growth, evidenced by a staggering 70.7% revenue growth and a best-in-class 63% profit margin. With a low 0.65 PEG ratio, the market is still underpricing the persistent compounding power of its AI solutions and software, which remains the crux of its long-term trajectory.
Moat. The company's formidable moat stems from its proprietary accelerated computing and networking platforms, particularly its GPUs and AI software, which create high switching costs for customers building complex AI models. This deep integration and category leadership in data center AI infrastructure underpins its exceptional 81.7% ROE, reflecting significant pricing power and capital efficiency.
Risk. The primary bear case centers on NVIDIA's elevated valuation and the cyclical nature of its core markets, particularly if demand for data center AI infrastructure cools or competition intensifies. A P/S TTM of 20.2 suggests significant future growth is already priced in, making it vulnerable to any deceleration from its 70.7% revenue growth. A sustained decline in data center segment growth rates would confirm the bear thesis.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $441.60 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $655.09 if current growth sustains into durable earnings power.
9. HRMY — Harmony Biosciences Holdings, Inc. · score 84.9
Biotechnology · price $36.84 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 14.9x A- · PEG 0.69 A-
Why now. Harmony's cash‑generating WAKIX narcolepsy franchise is the anchor for a pipeline that will unlock new rare‑neurology markets – PWS and Myotonic Dystrophy – creating a multi‑product growth engine. The business is already scaling, delivering 20.7% YoY revenue growth, 16.2% profit margin and a PEG of 0.69, meaning earnings are expanding faster than the market expects at a modest valuation. The thesis rests on the compounding of pitolisant’s market share and the upside of Phase 3/2 trials that can double the addressable revenue base within the next few years.
Moat. WAKIX’s novel histamine‑H3 antagonism gives Harmony a first‑to‑market advantage in the U.S. narcolepsy space, protected by patents through the 2030s and a specialty‑pharmacy distribution network that locks in neurologists and sleep‑disorder clinics. This IP barrier creates pricing power and high switching costs for patients, while the same chemistry underpins the PWS and DM1 programs, extending the moat across multiple rare‑neurology indications.
Risk. The company’s upside hinges on successful Phase 3 results for PWS; a miss would leave Harmony overly dependent on a single commercial product, exposing it to competitive pressure from emerging generic H3 antagonists. The current PE of 14.9, while modest, already reflects a premium for that single‑product risk, and any margin compression below the 16.2% level would trigger a sell‑off. A negative trial readout would be the concrete signal that validates the bear case.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
10. ADMA — ADMA Biologics, Inc. · score 83.9
Biotechnology · price $9.08 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 13.4x A- · PEG 0.68 A-
Why now. ADMA’s dominance in the U.S. IVIG market via BIVIGAM and ASCENIV fuels a durable revenue engine, underpinned by a 32.4% profit margin, a 42.4% ROE, and a sub‑1.0 PEG of 0.68 that signals outsized earnings growth at a modest valuation; the compounding driver is the expanding pool of primary humoral immunodeficiency patients that lock in repeat, high‑margin dosing.
Moat. ADMA controls a proprietary plasma collection network that supplies its specialty biologics, creating a supply‑side barrier and pricing power in the IVIG category; this vertical integration translates into the observed 42.4% ROE, as the company can capture the spread between collection costs and premium product pricing that rivals cannot quickly replicate.
Risk. The business is heavily weighted toward IVIG sales, leaving it vulnerable to any biosimilar entry or pricing pressure, while a debt‑to‑equity of 1.11 raises leverage concerns; a margin dip below the current 32.4% or a spike in debt would validate the bear view, and a sustained drop in IVIG demand would trigger a sharp price correction.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
11. CARG — CarGurus, Inc. · score 83.8
Auto & Truck Dealerships · price $34.18 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 18.0x B+ · PEG 1.04 B+
Why now. CarGurus’ Digital Deal platform is turning its massive shopper audience into a high‑margin, recurring revenue engine, and that engine is humming at a 15.9% profit margin while revenue still climbs 14% YoY. The business converts that margin into a stellar ROE of 62.9%, meaning each dollar of equity fuels outsized earnings growth. As long as Digital Deal scales, the compounding of cash flow and earnings will keep the growth engine alive.
Moat. The moat lives in CarGurus’ integrated marketplace that locks dealers into subscription fees and advertising spend while giving shoppers a single, data‑rich portal. Dealer subscription creates a sticky revenue stream because switching costs are high – dealers lose access to the platform’s lead flow and Digital Deal tools. This network effect, combined with the company’s ability to monetize the same audience across multiple products, locks in both supply and demand.
Risk. The biggest headwind is the elevated valuation: a forward P/E of 18 is high for a growth name, and any slowdown in revenue growth below the current 14% YoY would compress margins and ROE, eroding the premium. A dip in the 52‑week range toward the low of $26.39 would signal that the market is penalizing the stock for growth fatigue. A sustained miss on revenue growth would trigger a sell‑off and break the compounding thesis.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 83.4
Information Technology Services · price $83.89 · 1Y $139.06 · 5Y $203.60 · 10Y $302.02
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.1x A · PEG 0.43 A
Why now. EPAM’s platform‑engineering and cloud services are the engine of enterprise digital transformation, and that engine is revving at a 14.2% revenue growth rate, backed by a robust $544 m free cash flow and an ultra‑low 0.08 debt‑to‑equity ratio. The combination of high‑margin software services and a PEG of just 0.43 means earnings are cheap relative to growth, giving investors a clear upside as the company compounds its top‑line. The whole thesis rests on EPAM’s ability to keep locking in multi‑year digital‑platform contracts that fuel this compounding engine.
Moat. EPAM’s moat lies in its end‑to‑end digital platform engineering suite—requirements analysis, cloud road‑mapping, AI‑driven analytics, and smart‑automation operations—all delivered under a single contract, creating massive switching costs for large enterprises. Its ROE of 11.3% stems from pricing power in high‑value, bespoke software projects that few pure‑play consultancies can replicate quickly, cementing a durable competitive edge.
Risk. The biggest headwind is the market’s sensitivity to a slowdown in enterprise IT spend; EPAM’s beta of 1.43 amplifies any macro‑risk, and a deceleration from the current 14.2% growth would compress margins and pressure the 12.1× P/E. A sustained drop below the 52‑week low of $73 would signal that the growth engine is faltering and could trigger a sell‑off, breaking the bull case.
Horizon. 1-3 yr $139.06 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $203.60 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $302.02 if current growth sustains into durable earnings power.
13. IT — Gartner, Inc. · score 82.9
Information Technology Services · price $133.24 · 1Y $164.23 · 5Y $240.45 · 10Y $356.69
FCF $1.3b C+ · Rev +2.3% C · D/E n/a · P/E 13.2x A · PEG 0.54 A-
Why now. Gartner’s recurring Insights subscriptions lock enterprise decision‑makers into a high‑margin data engine, fueling compounding cash generation. The business already produces $1.3B of free cash flow, trades at a modest PE of 13.2x and a sub‑1.0 beta of 0.96, while still delivering 2.3% revenue growth YoY – the trifecta that proves the subscription engine can keep scaling without sacrificing valuation. The whole thesis hinges on the Insight segment’s ability to keep expanding its subscriber base and deepen usage.
Moat. The Insights segment’s subscription model creates multi‑year contracts and a proprietary benchmark database that customers cannot replace without costly re‑tooling, while the Conferences segment reinforces relationships through exclusive executive networking. This combination yields high switching costs and a data moat that competitors cannot replicate quickly.
Risk. Growth has stalled at just 2.3% revenue YoY, far below the sector’s typical double‑digit expansion, and the stock still sits far below its 52‑week high of $375.84, suggesting the market may have over‑priced past growth expectations. A further slowdown in subscription renewals or a margin squeeze would validate the bearish view, with the price sliding back toward the lower end of the analyst range ($120).
Horizon. 1-3 yr $164.23 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $240.45 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $356.69 if current growth sustains into durable earnings power.
14. RMD — ResMed Inc. · score 82.8
Medical Instruments & Supplies · price $203.87 · 1Y $256.07 · 5Y $374.91 · 10Y $556.15
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 19.6x A- · PEG 1.20 B+
Why now. ResMed’s moat is its cloud‑connected diagnostic platform—devices like NightOwl and ApneaLink Air lock providers into a recurring software ecosystem that fuels sticky revenue. That stickiness is already delivering 10.3% YoY revenue growth, a healthy 27.4% profit margin, and a stellar 23.4% ROE, proving the business can compound earnings while expanding its addressable market. The thesis rests on the continued roll‑out of these integrated hardware‑software solutions across sleep clinics and home care, which should keep the growth engine humming.
Moat. The advantage lives in ResMed’s end‑to‑end solution: clinicians buy the diagnostic device and then stay for the cloud‑based therapy management software, creating high switching costs and data lock‑in. This platform enables pricing power in the sleep‑health segment, which translates into the >20% ROE—a direct result of premium pricing on a differentiated, regulated device‑software combo that rivals can’t replicate quickly.
Risk. The bear case hinges on a slowdown in the core sleep‑health market; a dip in revenue growth below the current 10.3% YoY would expose the stock’s P/E of 19.6 as over‑valued for a growth name, while margin compression below the 27.4% profit margin would erode cash flow. A sustained miss on growth or margin would be the signal that the growth premium is unjustified and the bull thesis collapses.
Horizon. 1-3 yr $256.07 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $374.91 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $556.15 if current growth sustains into durable earnings power.
15. DXCM — DexCom, Inc. · score 82.7
Medical Devices · price $74.96 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 32.2x C+ · PEG 1.40 B
Why now. DexCom is a high-quality compounder poised for sustained growth by strategically expanding its Continuous Glucose Monitoring (CGM) market beyond traditional insulin users, notably with products like Stelo targeting adults with prediabetes and Type 2 diabetes who do not use insulin. This market expansion fuels a robust 16.1% FY YoY revenue growth, translating into a healthy 19.3% profit margin and generating $1.4B in free cash flow. The entire thesis rests on DexCom's ability to successfully penetrate these massive, underserved patient populations with its innovative CGM solutions.
Moat. DexCom's durable edge stems from its continuous innovation in integrated CGM systems like Dexcom G7 and G7 15 Day, coupled with direct marketing to endocrinologists and physicians, creating significant switching costs and deep entrenchment in diabetes management. The company's impressive 31.5% Return on Equity indicates strong pricing power and efficient capital allocation, likely driven by its established technology leadership and regulatory approvals in the specialized medical device market for glucose monitoring, making it difficult for competitors to quickly replicate its product ecosystem and market access.
Risk. The primary bear case against DexCom centers on its elevated valuation, with a P/E TTM of 32.2, suggesting that substantial future growth is already priced into the stock. This leaves the company vulnerable to any deceleration in its core revenue growth or increased competitive pressures from alternative glucose monitoring technologies or new market entrants. A sustained deceleration in revenue growth below the current 16.1% or a contraction in the 19.3% profit margin would be a concrete signal confirming that competitive dynamics are eroding the bull thesis.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
16. VEEV — Veeva Systems Inc. · score 82.3
Health Information Services · price $190.12 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 33.6x C+ · PEG 0.86 B+
Why now. Veeva’s Vault CRM Suite locks pharma and biotech customers into a unified cloud stack, fueling a 16.2% YoY revenue growth while delivering a 28.4% profit margin and a sub‑1× PEG of 0.86—the perfect compounding engine for a growth‑oriented name. The thesis rests on the relentless expansion of life‑science cloud adoption, which guarantees recurring cash and margin accretion.
Moat. The Veeva Commercial Cloud, especially Vault CRM and Data Cloud, creates massive switching costs because customers embed the platform across sales, medical, and analytics workflows, making migration prohibitively expensive. Coupled with a near‑zero debt‑to‑equity of 0.01, this entrenches cash flow and lets Veeva reinvest at high efficiency, reinforcing its leadership in the life‑sciences SaaS niche.
Risk. At a forward P/E of 33.6 the stock trades at a premium that assumes sustained high‑double‑digit growth; any slowdown below the 16% revenue clip would compress multiples quickly. A bear‑case signal would be a quarterly revenue growth dip under 10% or margin erosion, which would force the valuation down toward the 52‑week low of $148.05.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
17. CVSA — Covista Inc. · score 80.2
Education & Training Services · price $130.90 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +9.7% B · D/E 0.54 B+ · P/E 19.1x B · PEG 0.88 B+
Why now. Covista Inc. is a compelling growth compounder, capitalizing on the persistent demand for skilled professionals through its specialized healthcare education and Medical and Veterinary segments. A healthy 9.7% FY YoY revenue growth, coupled with a robust 12.3% profit margin and an attractive 0.88 PEG ratio, points to a business effectively converting market need into shareholder value. The crux of the thesis rests on the continued, non-cyclical demand for its niche educational programs, ensuring a stable and growing student base.
Moat. Covista's durable edge stems from its established and accredited institutions like Chamberlain University and American University of the Caribbean, which offer specialized degree programs in high-demand fields such as nursing and medical professions. The significant regulatory hurdles and the deep curriculum required for these specific healthcare education programs create high barriers to entry and strong switching costs for students, making it difficult for new competitors to replicate its offerings quickly.
Risk. The primary bear case for Covista Inc. centers on potential regulatory headwinds or shifts in public perception regarding private postsecondary education, particularly within its Chamberlain and Walden University segments. While revenue growth is solid at 9.7% FY YoY, any deceleration could make the current 19.1 P/E multiple appear stretched, especially if coupled with increasing scrutiny on student outcomes or loan defaults. A concrete signal confirming the bear case would be a sustained decline in new student enrollments or adverse legislative changes impacting federal funding for its specialized healthcare education programs.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
18. PODD — Insulet Corporation · score 79.4
Medical Devices · price $161.28 · 1Y $238.67 · 5Y $349.43 · 10Y $518.36
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 37.8x C+ · PEG 1.42 B
Why now. The Omnipod 5 automated insulin delivery system is unlocking a new wave of adoption, propelling Insulet’s top line at a blistering 31.9% revenue growth while generating $416 m of free cash flow and delivering a premium 23.2% ROE. The combination of a proprietary AID algorithm, Bluetooth integration and a lock‑in pod design creates a high‑margin, recurring revenue engine that will keep compounding for years. The thesis hinges on the Omnipod platform’s ability to dominate the U.S. and international insulin‑pump market and sustain double‑digit growth.
Moat. Insulet’s moat stems from the Omnipod ecosystem: a fully disposable pod with embedded AID software that talks wirelessly to any third‑party CGM, forcing patients and clinicians to stay within a proven, FDA‑cleared workflow. The pod’s convenience and the proprietary algorithm generate pricing power, reflected in a >20% ROE, and the high switching cost of re‑training patients locks in revenue. Competitors must rebuild both hardware and software integration, a barrier that cannot be rushed.
Risk. The stock trades at a lofty PE of 37.8 and a PEG of 1.42, implying the market has already priced in aggressive growth; any slowdown from the current 31.9% revenue growth would compress multiples sharply. A debt‑to‑equity of 0.78 adds leverage risk if cash conversion falters, and a beta of 1.11 magnifies downside in a volatile market. A miss on Omnipod 5 adoption or a regulatory setback would push the price back toward the 52‑week low of $138.79, confirming the bear case.
Horizon. 1-3 yr $238.67 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $349.43 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $518.36 if current growth sustains into durable earnings power.
19. MELI — MercadoLibre, Inc. · score 79.1
Internet Retail · price $1852.22 · 1Y $2,209 · 5Y $3,234 · 10Y $4,797
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 48.8x C · PEG 1.14 B+
Why now. MercadoLibre’s compounding engine is the seamless integration of Mercado Pago into its Marketplace, locking merchants and shoppers into a single financial‑commerce loop. Revenue is soaring +36.4% YoY, fueling a free cash flow pile of $11.8 B and a PEG of 1.14, proving growth is still cheap relative to earnings acceleration. The thesis rests on the relentless expansion of digital payments across Brazil, Mexico, and Argentina, which will keep the cash‑flow engine humming.
Moat. The Marketplace‑to‑Pago network creates a two‑sided lock‑in: sellers rely on Mercado Pago for checkout and financing, while buyers stay for the breadth of listings, generating a high‑margin moat that drives the 26.4% ROE. This virtuous cycle is hard to replicate because new entrants must build both a trusted marketplace and a full‑stack fintech suite from scratch.
Risk. The stock trades at a lofty P/E of 48.8 and a debt‑to‑equity of 1.7, leaving little cushion if revenue growth slows or margins compress; a beta of 1.34 adds volatility. A bear signal would be a slowdown to sub‑30% revenue growth or a margin dip below 8%, which would force the valuation down toward the 52‑week low of $1,495.
Horizon. 1-3 yr $2,209 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,234 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,797 if current growth sustains into durable earnings power.
20. FIVE — Five Below, Inc. · score 78.8
Specialty Retail · price $189.39 · 1Y $260.33 · 5Y $381.15 · 10Y $565.42
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 23.9x B · PEG 0.98 B+
Why now. Five Below, Inc. is a compelling growth story, capitalizing on its unique position as a specialty value retailer with a broad and appealing product assortment. The company's impressive 25.9% FY YoY revenue growth, coupled with a healthy 8.7% profit margin and a PEG ratio of 0.98, indicates efficient expansion and undervalued growth. The crux of the thesis rests on Five Below's ability to consistently open new stores and refresh its diverse product lines, from "classic and novelty candy bars" to "personalized living space products," driving sustained customer engagement and top-line compounding.
Moat. Five Below's durable edge stems from its highly specialized value retail model, which offers a constantly evolving assortment of "personal care essentials, skincare, fragrance, and branded cosmetics" alongside "party goods, decorations, gag gifts, greeting cards" at price points difficult for competitors to match. This creates a treasure-hunt shopping experience that fosters repeat visits and customer loyalty, making it challenging for general merchandisers to replicate. The company's robust ROE of 19% is a testament to its efficient inventory management and rapid turnover of novelty and seasonal items, underpinning a cost advantage that fuels its aggressive pricing strategy.
Risk. The primary bear case for Five Below centers on the potential for increased competition within the "specialty value retail" segment, particularly from online discounters or larger retailers expanding their "novelty décor" and "accent furniture" offerings, which could erode pricing power. While the company exhibits strong growth, its P/E of 23.9, though reasonable for a growth stock, offers limited cushion if its impressive 25.9% revenue growth rate were to significantly decelerate. A sustained decline in profit margin below 8% or a material slowdown in new store openings would serve as a concrete signal confirming that competitive pressures are impacting the core business model.
Horizon. 1-3 yr $260.33 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.15 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $565.42 if current growth sustains into durable earnings power.
21. DECK — Deckers Outdoor Corporation · score 78.4
Footwear & Accessories · price $105.99 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.1x B+ · PEG 1.32 B
Why now. Deckers' HOKA performance‑running franchise is the engine of compounding, delivering 9.8% revenue growth YoY, 41% ROE and $1.1 B of free cash flow on a modest 15.1× PE and low 0.15 debt‑to‑equity, giving it the cash to reinvest and buy back shares. The thesis rests on HOKA’s continued premium pricing power in the high‑growth running market, which should keep the compounder humming for years.
Moat. HOKA’s category leadership in performance running creates a pricing premium that translates into the 41% ROE, while Deckers’ multi‑brand distribution network (UGG, Teva, Koolaburra) locks in shelf space and reduces channel switching for consumers. The low debt base (0.15 D/E) lets the company fund growth without dilutive financing, a barrier competitors in the footwear space struggle to match.
Risk. A slowdown in premium athletic footwear demand would compress margins and stall the 9.8% growth rate, while a PE of 15.1—high for a pure‑play growth name—signals the market may already price in continued expansion. A breach below the 52‑week low of $78.91 or a consensus downgrade would confirm the bear case.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
22. NFLX — Netflix, Inc. · score 77.9
Entertainment · price $73.37 · 1Y $113.15 · 5Y $165.66 · 10Y $245.74
FCF $11.9b A- · Rev +16.7% B+ · D/E 0.54 B · P/E 23.7x B · PEG 1.44 B
Why now. Netflix’s global streaming platform compounds earnings by continuously expanding its multilingual content library, fueling a 16.7% revenue growth YoY, a razor‑thin 28.5% profit margin, and an industry‑leading 43% ROE. The relentless churn of new series, documentaries, and games locks in subscriber stickiness, ensuring the growth engine stays hot. The whole thesis rests on that content‑driven compounding persisting as the world streams more.
Moat. The moat lives in Netflix’s proprietary recommendation engine and its ever‑growing, globally‑licensed content vault, which creates high switching costs for members who have curated watchlists across languages and devices. This pricing power, reflected in a 43% ROE, lets Netflix charge premium subscription fees that rivals can’t match without comparable content depth.
Risk. The bear case centers on intensifying competition from other streaming services that can erode subscriber growth, while Netflix trades at a lofty 23.7× P/E and a beta of 1.52, suggesting the market has already priced in future growth. A slowdown in revenue growth or margin compression would push the valuation down, and a rise in debt‑to‑equity above the current 0.54 would signal financial strain. A sustained dip in subscriber acquisition or a margin drop below 25% would confirm the downside.
Horizon. 1-3 yr $113.15 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $165.66 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $245.74 if current growth sustains into durable earnings power.
23. META — Meta Platforms, Inc. · score 76.8
Internet Content & Information · price $669.21 · 1Y $828.34 · 5Y $1,213 · 10Y $1,799
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 24.3x B · PEG 0.97 B+
Why now. Meta’s Family of Apps is locked into a virtuous growth loop, delivering 26.2% YoY revenue growth, 32.8% profit margin and a stellar 29% ROE that together fuel compounding cash flow; the platform’s expanding ad inventory and AI‑enhanced engagement lock in users and advertisers, guaranteeing the next wave of earnings. The thesis hinges on the FoA segment’s ability to keep scaling margins as it monetizes deeper user data, turning every incremental user hour into high‑margin revenue.
Moat. The FoA network effect creates a self‑reinforcing moat: billions of users generate data that powers more relevant ads, which attract more advertisers, raising pricing power and sustaining the 29% ROE. Switching costs are massive because brands and creators embed their audiences across Facebook, Instagram and Messenger, a lock‑in that competitors cannot replicate quickly.
Risk. The market is pricing a premium on growth, reflected in a lofty PE ratio of 24.3 and a beta of 1.25, leaving little cushion if revenue decelerates or Reality Labs drags margins lower. A sustained slowdown in ad spend or a misstep in the RL segment would push the stock back toward its 52‑week low of $520.26, confirming the bear case.
Horizon. 1-3 yr $828.34 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,213 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,799 if current growth sustains into durable earnings power.
24. MU — Micron Technology, Inc. · score 76.7
Semiconductors · price $979.30 · 1Y $1,486 · 5Y $2,176 · 10Y $3,227
FCF $26.2b A · Rev +167.0% A · D/E 0.06 A- · P/E 22.1x B+ · PEG 0.14 A
Why now. Micron’s explosive 167% FY YoY revenue growth is being powered by its Cloud and Core Data Center Memory Business Units, where demand for CXL‑based and high‑bandwidth memory is exploding. Coupled with an industry‑shattering ROE of 50.1% and a massive $26.2 B of free cash flow, the company can reinvest at scale while returning cash to shareholders, making the current PE of 22.1 a bargain for a megacap growth engine. The thesis rests on continued compounding of data‑center memory spend as AI and cloud workloads expand.
Moat. Micron’s moat lies in its integrated memory‑in‑package (MCP) and CXL‑based solutions that lock in hyperscale cloud customers who face massive switching costs to re‑architect their servers. Its scale‑driven cost advantage lets it price premium high‑bandwidth products, translating the 50.1% ROE into sustainable pricing power that rivals can’t match quickly.
Risk. The stock’s beta of 2.14 makes it extremely sensitive to a tech‑cycle slowdown, and the 22.1 PE, while low for growth, is still elevated if data‑center spend stalls, which would crush the 167% revenue surge. A sustained slowdown in AI‑driven memory demand, reflected in a widening PE gap or a dip below the 52‑week low, would confirm the bear case and topple the bull thesis.
Horizon. 1-3 yr $1,486 (analyst consensus (n=42)) — fundamentals + valuation re-rating. 5 yr $2,176 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $3,227 if current growth sustains into durable earnings power.
25. YUMC — Yum China Holdings, Inc. · score 76.4
Restaurants · price $43.02 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 16.5x B+ · PEG 1.08 B+
Why now. YUMC is a compelling growth compounder, leveraging its established multi-brand presence and digital leadership in the vast Chinese market. The company's expansion across its diverse restaurant concepts like KFC, Pizza Hut, and Lavazza, coupled with robust online food delivery services, continues to drive market share in the People's Republic of China. This strategy generates substantial free cash flow of $931m, supports a healthy revenue growth of 6.7%, and is currently trading at an attractive P/S ratio of 1.2, indicating undervaluation relative to its growth prospects. The crux of the thesis rests on its ability to continuously adapt and expand its localized offerings to capture the evolving preferences of Chinese consumers.
Moat. YUMC's durable edge stems from its unparalleled scale and localized operational expertise across its portfolio of brands, including KFC, Pizza Hut, and Huang Ji Huang, throughout the People's Republic of China. Its integrated online food delivery services create a powerful network effect, making it difficult for new entrants to replicate its reach and convenience. This extensive infrastructure and deep market penetration contribute to a robust ROE of 17.4%, reflecting efficient capital deployment and sustained profitability.
Risk. The primary threat to YUMC is intensified competition within China's dynamic restaurant sector, alongside the potential for rapid shifts in consumer tastes or adverse regulatory changes impacting its foreign-originated brands. Despite its "growth" classification, the company's revenue growth of 6.7% could decelerate, making its P/E of 16.5 appear less attractive, especially with the stock currently trading near its 52-week low of $40.15. A sustained decline in customer traffic across its core KFC and Pizza Hut segments, or a significant increase in food and labor costs, would confirm the bear thesis.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
26. FISV — Fiserv, Inc. · score 76
Sector n/a · price $50.45 · 1Y $67.56 · 5Y $85.29 · 10Y $109.38
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.6x A- · PEG 2.37 C
Why now. Sector n/a · market cap $26.9b. Down 70% from 52-week high of $168.93 — deep drawdown territory. 27 sell-side analysts rate this a Hold with a mean 1-yr target of $67.56 (implying +34% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 70% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $67.56 (analyst consensus (n=27)) — multiple re-rating thesis requires a catalyst. 5 yr $85.29 at ~11% CAGR — dividend + buyback compounding. 10 yr $109.38 if the moat survives secular pressure.
27. DEO — Diageo plc · score 75.7
Beverages - Wineries & Distilleries · price $82.03 · 1Y $101.14 · 5Y $148.08 · 10Y $219.67
FCF n/a · Rev +4.8% C+ · D/E 1.77 C · P/E 18.9x B · PEG 0.80 A-
Why now. Beverages - Wineries & Distilleries · market cap $45.6b. Down 30% from 52-week high of $116.41 — deep drawdown territory. PEG 0.80 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $101.14 (implying +23% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Dividend payout 96% of earnings on a 4.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Horizon. 1-3 yr $101.14 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $148.08 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $219.67 if current growth sustains into durable earnings power.
28. ULTA — Ulta Beauty, Inc. · score 75.3
Specialty Retail · price $469.20 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 17.6x B+ · PEG 1.63 C+
Why now. Specialty Retail · market cap $20.2b. Down 34% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +33% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 34% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
29. CVNA — Carvana Co. · score 74.9
Auto & Truck Dealerships · price $65.83 · 1Y $92.14 · 5Y $134.91 · 10Y $200.12
FCF $740m C+ · Rev +51.7% A · D/E 1.21 B · P/E 38.3x C · PEG 0.79 A-
Why now. Auto & Truck Dealerships · market cap $72.2b. Down 32% from 52-week high of $97.38 — deep drawdown territory. Revenue growing +52% — in hypergrowth territory. PEG 0.79 — paying under fair value for the growth rate. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $92.14 (implying +40% upside).
Moat. ROE 39% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $72.2b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 3.46 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 38x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $92.14 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $134.91 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $200.12 if current growth sustains into durable earnings power.
30. APP — AppLovin Corporation · score 74.3
Advertising Agencies · price $506.98 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 44.0x C · PEG 1.39 B
Why now. Advertising Agencies · market cap $170.3b. Down 32% from 52-week high of $745.61 — deep drawdown territory. Revenue growing +66% — in hypergrowth territory. 30 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $654.60 (implying +29% upside).
Moat. Net margin 64% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 112% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $170.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 2.48 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 44x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.